| Nome |
# |
|
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data, file de164cb4-718d-6b31-e053-1705fe0a395c
|
22
|
|
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review, file de164cb4-72af-6b31-e053-1705fe0a395c
|
18
|
|
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment., file de164cb4-5580-6b31-e053-1705fe0a395c
|
16
|
|
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine., file de164cb3-ffec-6b31-e053-1705fe0a395c
|
9
|
|
Raman Spectroscopic Stratification of Multiple Myeloma Patients
Based on Exosome Profiling, file de164cb4-3389-6b31-e053-1705fe0a395c
|
8
|
|
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells, file c90dd740-b4a3-44fe-9058-970b00ed611e
|
6
|
|
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia, file bd2fc93e-50af-4405-b3db-9d6b41d3786a
|
5
|
|
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma., file de164cb3-e7b3-6b31-e053-1705fe0a395c
|
5
|
|
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report, file de164cb4-73a9-6b31-e053-1705fe0a395c
|
5
|
|
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia, file 3f6387b2-7039-4c07-877c-7ec592547550
|
4
|
|
Pharmacogenomics biomarker discovery and validation for translation in clinical practice., file 97a61678-aa86-481f-ac25-db64e08ac131
|
4
|
|
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling, file de164cb3-ca3a-6b31-e053-1705fe0a395c
|
4
|
|
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma, file de164cb4-34eb-6b31-e053-1705fe0a395c
|
4
|
|
Risk Alleles for Multiple Myeloma Susceptibility in ADME Genes, file de164cb4-77ba-6b31-e053-1705fe0a395c
|
4
|
|
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity, file 0a1f4ac7-c97c-4e44-b9af-fece5b0795b0
|
3
|
|
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells, file 847d9d96-3f2b-4e5b-956e-256964574de9
|
3
|
|
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth, file c3402005-a874-4b5b-8324-b85490a7467c
|
3
|
|
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence, file de164cb3-d8d8-6b31-e053-1705fe0a395c
|
3
|
|
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1, file de164cb3-e216-6b31-e053-1705fe0a395c
|
3
|
|
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy, file de164cb3-e7e7-6b31-e053-1705fe0a395c
|
3
|
|
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor, file de164cb3-e7e8-6b31-e053-1705fe0a395c
|
3
|
|
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials, file de164cb3-e7ec-6b31-e053-1705fe0a395c
|
3
|
|
A gene expression inflammatory signature specifically predicts
multiple myeloma evolution and patients survival, file de164cb3-e7ed-6b31-e053-1705fe0a395c
|
3
|
|
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells, file de164cb3-e7f2-6b31-e053-1705fe0a395c
|
3
|
|
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma, file de164cb3-f754-6b31-e053-1705fe0a395c
|
3
|
|
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients, file de164cb4-2072-6b31-e053-1705fe0a395c
|
3
|
|
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma, file de164cb3-bf0b-6b31-e053-1705fe0a395c
|
2
|
|
Transcriptional regulation of the mismatch repair gene hMLH1, file de164cb3-c413-6b31-e053-1705fe0a395c
|
2
|
|
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma., file de164cb3-c735-6b31-e053-1705fe0a395c
|
2
|
|
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth, file de164cb3-db14-6b31-e053-1705fe0a395c
|
2
|
|
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma, file de164cb3-e7e9-6b31-e053-1705fe0a395c
|
2
|
|
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone
marrow stromal cells and impairs the resorbing activity of mature osteoclasts, file de164cb3-e7f4-6b31-e053-1705fe0a395c
|
2
|
|
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells, file de164cb3-e937-6b31-e053-1705fe0a395c
|
2
|
|
The non-coding RNA landscape of plasma cell dyscrasias, file de164cb4-164d-6b31-e053-1705fe0a395c
|
2
|
|
MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches, file de164cb4-4a52-6b31-e053-1705fe0a395c
|
2
|
|
The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple
myeloma cells, file de164cb4-5e46-6b31-e053-1705fe0a395c
|
2
|
|
Integration of DNA Microarray with Clinical and Genomic Data, file 32c14112-b2cb-487e-b01b-62714296b3d0
|
1
|
|
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics, file ac957746-229a-44ae-9702-462d0bbad54a
|
1
|
|
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties, file ae6fcf71-3fc0-4d2d-9d36-428de329e960
|
1
|
|
Automatic summarisation and annotation of microarray data, file de164cb3-bb39-6b31-e053-1705fe0a395c
|
1
|
|
Analysis of miRNA, mRNA, and TF interactions through network-based methods, file de164cb3-bdbe-6b31-e053-1705fe0a395c
|
1
|
|
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells, file de164cb3-c923-6b31-e053-1705fe0a395c
|
1
|
|
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells, file de164cb3-d982-6b31-e053-1705fe0a395c
|
1
|
|
Mass spectrometry-based identification of the tumor antigen UN1 as the transmembrane CD43 sialoglycoprotein, file de164cb3-dbdb-6b31-e053-1705fe0a395c
|
1
|
|
DMET™ (Drug Metabolism Enzymes and Transporters): a
pharmacogenomic platform for precision medicine, file de164cb3-dc0b-6b31-e053-1705fe0a395c
|
1
|
|
Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study, file de164cb3-de3f-6b31-e053-1705fe0a395c
|
1
|
|
Aurora Kinase A expression predicts
platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma
patients, file de164cb3-deb9-6b31-e053-1705fe0a395c
|
1
|
|
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study., file de164cb3-df30-6b31-e053-1705fe0a395c
|
1
|
|
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management?, file de164cb3-df6b-6b31-e053-1705fe0a395c
|
1
|
|
In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma, file de164cb3-e09a-6b31-e053-1705fe0a395c
|
1
|
|
Identification of polymorphic variants associated with
erlotinib-related skin toxicity in advanced non-small cell lung cancer patients
by DMET microarray analysis, file de164cb3-e141-6b31-e053-1705fe0a395c
|
1
|
|
In vitro and in vivo activity of a novel locked nucleic acid
(LNA)-inhibitor-miR-221 against multiple myeloma cells, file de164cb3-e380-6b31-e053-1705fe0a395c
|
1
|
|
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92, file de164cb3-e386-6b31-e053-1705fe0a395c
|
1
|
|
null, file de164cb3-e7c0-6b31-e053-1705fe0a395c
|
1
|
|
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma, file de164cb3-e7ea-6b31-e053-1705fe0a395c
|
1
|
|
MicroRNA
and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic
Approaches, file de164cb3-e7eb-6b31-e053-1705fe0a395c
|
1
|
|
MicroRNAs in multiple myeloma and related
bone disease, file de164cb3-e7ef-6b31-e053-1705fe0a395c
|
1
|
|
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario, file de164cb3-e7f0-6b31-e053-1705fe0a395c
|
1
|
|
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells, file de164cb3-e7f1-6b31-e053-1705fe0a395c
|
1
|
|
null, file de164cb3-e7f7-6b31-e053-1705fe0a395c
|
1
|
|
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity., file de164cb3-eab8-6b31-e053-1705fe0a395c
|
1
|
|
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo, file de164cb3-f48e-6b31-e053-1705fe0a395c
|
1
|
|
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma, file de164cb3-f75c-6b31-e053-1705fe0a395c
|
1
|
|
Physicochemical features and transfection properties of chitosan/poloxamer 188/poly(D,L-lactide-co-glycolide) nanoplexes, file de164cb4-13fe-6b31-e053-1705fe0a395c
|
1
|
|
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease, file de164cb4-2564-6b31-e053-1705fe0a395c
|
1
|
|
Circulating biomarkers in osteosarcoma: new translational tools for diagnosis and treatment., file de164cb4-4b6d-6b31-e053-1705fe0a395c
|
1
|
|
Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu in vivo model of human multiple myeloma, file de164cb4-5130-6b31-e053-1705fe0a395c
|
1
|
|
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment., file de164cb4-557e-6b31-e053-1705fe0a395c
|
1
|
|
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine, file de164cb4-7703-6b31-e053-1705fe0a395c
|
1
|
|
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma, file ed155877-f84a-4dfe-9702-4f8a0d109f04
|
1
|
| Totale |
204 |